Bristol-Myers Squibb Company Drug Cocktail Stymies Melanoma Tumors

Published: May 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Two drugs from Bristol-Myers Squibb Co. (BMY) shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer. In the study, 52 patients were simultaneously treated with Bristol-Myers’s melanoma drug Yervoy and nivolumab, its experimental therapy that targets the immune system in a different way. Tumors shrank in 40 percent of patients, and in 53 percent of those who got the most effective dose combination, according to data released yesterday in advance of the American Society of Clinical Oncology meeting scheduled to begin May 31.

Help employers find you! Check out all the jobs and post your resume.

Back to news